Daiichi forks out for access to cancer database

Daiichi Sankyo (TYO: 4568) has agreed a deal that allows it exclusive access to the cancer target database of DarwinHealth, a privately-held US oncology specialist.

The database and technology were created to identify critical mechanisms linked to tumor dependencies and maintenance beyond genetic mutations, and include information on master regulators of specific tumor subtypes, as well as direct upstream modulators across more than 35 tumor and 90 tumor subtypes.

Gideon Bosker, chief executive of DarwinHealth, said: “The purpose of this agreement is to identify novel, high-value cancer targets that can subsequently be prioritized and undergo rigorous experimental validation to drive drug development for a new generation of anti-cancer therapies that would be designed, developed, and owned by Daiichi Sankyo.”